No Data
No Data
20-F: Registration statement / Annual report / Transition report
6-K: Notice of Resolutions at the 148th Ordinary General Meeting of Shareholders
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
OSAKA, Japan, June 26, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the "Annual Report") with the U.S. S
Wave Jumps on Trial Data for Huntington's Disease Therapy
Takeda Gets Japan Nod for First Post-transplant Anti-CMV Treatment
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Takeda (TAK) said Monday that its drug Livtencity has been approved by the Japan's Ministry of Health, Labour and Welfare for the treatment of cytomegalovirus disease that is resistant to existing the